Synthesis and characterization of antigenic influenza A M2e protein peptide-poly(acrylic) acid bioconjugate and determination of toxicity<i>in vitro</i>

Budama‐Kilinc, Yasemin; Mustafaeva, Zeynep; Çakır-Koç, Rabia; Bağırova, Melahat; Allahverdiyev, Adil M.

doi:10.4161/21655979.2014.969131

Cited by 10 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results showed an enhanced IgG serum antibody and mucosal secretory IgA antibody responses in nasal swabs, bronchoalveolar lavage (BAL) fluids, and lung lysates that were reactive against homologous (H1N2), heterologous (H1N1), and heterosubtypic (H3N2) viral strains. Influenza vaccine formulations were also created by use of other bioadhesive polymers [6,65], such as hyaluronic acid [288,289], alginate [290], starch [291], and poly(acrylic acid) [291,292].…”

Section: Vaccine Deliverymentioning

confidence: 99%

Polymer-Based Nanosystems—A Versatile Delivery Approach

Niculescu

Grumezescu

2021

Materials

View full text Add to dashboard Cite

Polymer-based nanoparticles of tailored size, morphology, and surface properties have attracted increasing attention as carriers for drugs, biomolecules, and genes. By protecting the payload from degradation and maintaining sustained and controlled release of the drug, polymeric nanoparticles can reduce drug clearance, increase their cargo’s stability and solubility, prolong its half-life, and ensure optimal concentration at the target site. The inherent immunomodulatory properties of specific polymer nanoparticles, coupled with their drug encapsulation ability, have raised particular interest in vaccine delivery. This paper aims to review current and emerging drug delivery applications of both branched and linear, natural, and synthetic polymer nanostructures, focusing on their role in vaccine development.

show abstract

Section: Vaccine Deliverymentioning

confidence: 99%

Polymer-Based Nanosystems—A Versatile Delivery Approach

Niculescu

Grumezescu

2021

Materials

View full text Add to dashboard Cite

show abstract

“…Preparation of AVP (4-5)-NH 2 peptide loaded CS NPs CS NPs were prepared using a simple ionic gelation process with some modifications as described elsewhere [37][38][39][40]. Optimization studies were conducted, and the effects of the concentration of chitosan, TPP and peptide to particles size, polydispersity index and zeta potential values were investigated.…”

Section: Ft-ir Analysismentioning

confidence: 99%

In Silico design of AVP (4–5) peptide and synthesis, characterization and in vitro activity of chitosan nanoparticles

et al. 2020

View full text Add to dashboard Cite

Background Arginine-vasopressin (AVP) is a neuropeptide and provides learning and memory modulation. The AVP (4-5) dipeptide corresponds to the N-terminal fragment of the major vasopressin metabolite AVP (4-9), has a neuroprotective effect and used in the treatment of Alzheimer's and Parkinson's disease. Methods The main objective of the present study is to evaluate the molecular mechanism of AVP (4-5) dipeptide and to develop and synthesize chitosan nanoparticle formulation using modified version of ionic gelation method, to increase drug effectiveness. For peptide loaded chitosan nanoparticles, the synthesized experiment medium was simulated for the first time by molecular dynamics method and used to determine the stability of the peptide, and the binding mechanism to protein (HSP70) was also investigated by molecular docking calculations. A potential pharmacologically features of the peptide was also characterized by ADME (Absorption, Distribution, Metabolism and Excretion) analysis. The characterization, in vitro release study, encapsulation efficiency and loading capacity of the peptide loaded chitosan nanoparticles (CS NPs) were performed by Dynamic Light Scattering (DLS), UV-vis absorption (UV), Scanning Electron Microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy techniques. Additionally, in vitro cytotoxicity of the peptide on human neuroblastoma cells (SH-SY5Y) was examined with XTT assay and the statistical analysis was evaluated. Results The results showed that; hydrodynamic size, zeta potential and polydispersity index (PdI) of the peptide-loaded CS NPs were 167.6 nm, +13.2 mV, and 0.211, respectively. In vitro release study of the peptide-loaded CS NPs showed that 17.23% of the AVP (4-5)-NH2 peptide was released in the first day, while 61.13% of AVP (4-5)-NH2 peptide was released in the end of the 10th day. The encapsulation efficiency and loading capacity were 99% and 10%, respectively. According to the obtained results from XTT assay, toxicity on SHSY-5Y cells in the concentration from 0.01 μg/μL to 30 μg/μL were evaluated and no toxicity was observed. Also, neuroprotective effect was showed against H 2 O 2 treatment. Conclusion The experimental medium of peptide-loaded chitosan nanoparticles was created for the first time with in silico system and the stability of the peptide in this medium was carried out by molecular dynamics studies. The binding sites of the peptide with the HSP70 protein were determined by molecular docking analysis. The size and morphology of the prepared NPs capable of crossing the blood-brain barrier (BBB) were monitored using DLS and SEM analyses, and the encapsulation efficiency and loading capacity were successfully performed with UV Analysis. In vitro release studies and in vitro cytotoxicity analysis on SHSY-5Y cell lines of the peptide were conducted for the first time.

show abstract

“…After forming a synthetic vaccine prototype, the cytotoxicity of the bioconjugate of the peptides and biopolymers is first determined (generally we use MTT analysis). After the apoptotic effect of the prototype on living cells is measured by flow cytometric detection, the vaccine prototype with the most viable cell number should be selected for further study [62]. After all these methods, immunization is the next step.…”

Section: Importance In Vitro and In Vivo Experiments Using Peptide-bamentioning

confidence: 99%

“…Thus, the most suitable peptidebased vaccine prototypes will be identified for future clinical phase studies. In brief, cell culture and toxicity studies are important before the analyses the effect of vaccine prototype in vivo [62].…”

Section: Importance In Vitro and In Vivo Experiments Using Peptide-bamentioning

confidence: 99%

New Generation Peptide-Based Vaccine Prototype

Özcan¹,

Karahan²,

Kumar³

et al. 2020

Current and Future Aspects of Nanomedicine

View full text Add to dashboard Cite

Synthetic peptide-based vaccine prototypes are the future potential vaccination. Antigens, which belong to minimal microbial component and produce antibodies such as peptides and polysaccharides, can promote long-term protection against pathogens that can cause infectious diseases. Production of peptides becomes simple with solid phase peptide synthesis and microwave-assisted solid phase peptide synthesis using automatic synthesizers. The use of synthetic peptides was approved by the health authorities for vaccine design. Peptides are themselves very weak immunogens and need adjuvants to provide an effective autoimmune response. For this reason, peptide antigens are conjugated with biopolymers and loaded with nanoparticles. The toxicity of vaccine prototypes is evaluated in cell culture, and non-toxic prototypes are selected for vaccinating experimental animals. The most effective peptide-based vaccine prototype is determined as the one with the highest antibody level. The goal of this book chapter is to illustrate the use of peptides vaccine systems and present their opportunities with their future development.

show abstract

Synthesis and characterization of antigenic influenza A M2e protein peptide-poly(acrylic) acid bioconjugate and determination of toxicityin vitro

Cited by 10 publications

References 18 publications

Polymer-Based Nanosystems—A Versatile Delivery Approach

Polymer-Based Nanosystems—A Versatile Delivery Approach

In Silico design of AVP (4–5) peptide and synthesis, characterization and in vitro activity of chitosan nanoparticles

New Generation Peptide-Based Vaccine Prototype

Contact Info

Product

Resources

About